From the Guidelines
Multiple Sclerosis Treatment Options
The primary disease-modifying therapies for Multiple Sclerosis (MS) include interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), and fingolimod (Gilenya), as evidenced by various clinical trials 1, 2.
- Other brand name medications used to treat MS include: + dimethyl fumarate (Tecfidera), which is administered orally at a dose of 240mg twice daily 2 + teriflunomide (Aubagio), with specific dosing regimens 2 + natalizumab (Tysabri), administered intravenously at a dose of 300mg every 4 weeks 2
- Additionally, medications like alemtuzumab (Lemtrada) and ocrelizumab (Ocrevus) are used for relapsing-remitting MS, with dosing regimens typically consisting of 12mg/day for 5 days initially, followed by 12mg/day for 3 days at 12 months 2. These therapies have been shown to have varying effects on brain atrophy and disability outcomes in clinical trials, with some demonstrating a positive effect on reducing accrual of atrophy 1, 2.
From the FDA Drug Label
What is AVONEX AVONEX is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Dimethyl fumarate delayed-release capsules are a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
What is TYSABRI TYSABRI is a prescription medicine used to treat adults with: relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
The brand names of drugs used to treat Multiple Sclerosis (MS) are:
- AVONEX (interferon beta-1a)
- TYSABRI (natalizumab)
- Dimethyl fumarate (no brand name mentioned in the provided text, but it is known to be marketed under the brand name Tecfidera) 3, 4, 5
From the Research
Disease-Modifying Therapies for Multiple Sclerosis
The following are some of the brand names of drugs used to treat Multiple Sclerosis (MS):
- Avonex (interferon beta-1a) 6, 7, 8, 9
- Rebif (interferon beta-1a) 6, 7, 8, 9
- Betaseron (interferon beta-1b) 6, 7, 8, 9
- Extavia (interferon beta-1b) 10, 9
- Copaxone (glatiramer acetate) 6, 7, 8, 9
- Tysabri (natalizumab) 6, 7, 10, 8, 9
- Gilenya (fingolimod) 6, 7, 10, 9
- Aubagio (teriflunomide) 7, 10, 9
- Tecfidera (dimethyl fumarate) 7, 10, 9
- Lemtrada (alemtuzumab) 6, 7, 10, 9
- Ocrevus (ocrelizumab) 6, 7, 9
Emerging Therapies
Some emerging therapies for MS include:
Treatment Strategies
Treatment strategies for MS include sequential monotherapy, escalation therapy, and induction and maintenance therapy 9.